Login
$SENS
$11.05 +$0.15 (1.38%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Timothy T. Goodnow Also a director
President and CEO
Title from the Form 4 dated Jun 15, 2026
64 Not stated $3,347,959
Frederick (“Rick”) Sullivan
Chief Financial Officer
42 Since 2022
4 years
$1,392,599
Mukul Jain
Chief Operating Officer
53 Since 2017
9 years
$1,945,166
Kenneth L. Horton
General Counsel and Corporate Development Advisor
59 Since 2017
9 years
Not reported
Brian Hansen Also a director
Chief Commercial Officer
Title from the Form 4 dated Jun 15, 2026
58 Not stated Not reported
Francine R. Kaufman Also a director
Chief Medical Officer
Title from the Form 4 dated Jun 15, 2026
75 Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
5 of 8
stated in the proxy
Average tenure
8.5 years
from year joined
Director Age On board Independent Committees 2025 pay Source
Timothy T. Goodnow
64 2015
11 years
Not independent None stated Paid as CEO
Francine R. Kaufman
75 2019
7 years
Not independent None stated Not stated
Brian Hansen
58 2024
2 years
Not independent None stated Not stated
Sharon Larkin
62 2021
5 years
Independent None stated $164,672
Steven Edelman
70 2016
10 years
Independent None stated $169,672
Edward J. Fiorentino
67 2015
11 years
Independent
Audit Committee
$174,672
Douglas S. Prince
72 2015
11 years
Independent None stated $183,172
Douglas A. Roeder
55 2015
11 years
Independent None stated $177,172

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

6 disclosed in the proxy filed Apr 6, 2026
Ascensia
an affiliate of PHC, which beneficially owns greater than 5% of our common stock
Amount not stated
2025

Amended and Restated Collaboration and Commercialization Agreement with Ascensia, which amended and restated the 2020 Commercialization Agreement and terminated Ascensia's U.S. marketing rights for Eversense

With the Company Open in proxy
Ascensia
an affiliate of PHC, which beneficially owns greater than 5% of our common stock
Amount not stated
effective January 1, 2026

Master asset purchase agreement under which the Company acquired Ascensia's assets related to Eversense marketing and distribution in the United States, effective January 1, 2026

With the Company Open in proxy
Ascensia
53% and 82% of total net revenues
years ended December 31, 2025 and 2024

Net revenue from the Company's distribution arrangement with Ascensia as a share of total net revenues

With the Company Open in proxy
Ascensia
$3.7 million
December 31, 2025

Commissions due from the Company to Ascensia at year end

With the Company Open in proxy
Ascensia
$5.3 million
December 31, 2025

Amount due from Ascensia to the Company at year end

With the Company Open in proxy
Ascensia
an affiliate of PHC, which beneficially owns greater than 5% of our common stock
Less than $0.1 million
years ended December 31, 2025 and 2024

Purchases of medical supplies from Ascensia for clinical trials

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support